[1] 中华医学会感染病学分会,慢性乙型肝炎防治指南(2019年版),中华传染病杂志,2019,37:711-736.
[2] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67:370-398.
[3] Terrault NA,Lok ASF,McMahon BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance.Hepatology,2018,67:1560-1599.
[4] Kim JH, Sinn DH. Low-level viremia in patients undergoing antiviraltherapy: Does it indicate time for a change? Clin Mol Hepatol,2020,26:315-317.
[5] Kim JH,Sinn DH,Kang W,et al. Low level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology,2017,66:335-343.
[6] Liu Y, Liu H, Hu Z, et al. Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination.Hepatology,2020,71:463-476.
[7] Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother,2007,60:201-205.
[8] Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018,68:672-681.
[9] Lee SB, Jeong J, Park JH,et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir.Clin Mol Hepatol,2020,26:364-375.
[10] 蔡大川,HBV高敏检测评估慢性乙型肝炎初治病毒学应答——一项横断面研究结果,2020紫禁城国际药师大会.
[11] Sun Y, Wu X, Zhou J, Meng T, et al. Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy.Clin Gastroenterol Hepatol,2020,18:2582-2591.
[12] Kim JH, Sinn DH, Kang W,et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology,2017, 66:335-343.
[13] Kim TS, Sinn DH, Kang W, et al. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. J Gastroenterol Hepatol,2019,34:2028-2035.
[14] Nam JY, Chang Y, Cho H,et al. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.J Viral Hepat,2018,25:552-560.
[15] Wong GL, Wong VW, Chan HY, et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther,2012,35:1326-35.
[16] JL Hou,W Zhao, YM Wang,et al. Randomized study of the relationship between virologic responses to entecavir or other HBV nucleos(t)ide analogues and long-term clinical outcomes in chinese patients with chronic hepatitis B virus infection. Hepatol Int, 2018,12,S341-S342.
[17] Xiong F, Bao X, Gu N,et al. The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk. Infect Genet Evol,2020,78:104101.
[18] Park JH, Ahn SJ, Cho HJ,et al. Clinical course of partial virological responders under prolonged entecavir monotherapy in patients with chronic hepatitis B. J Med Virol,2016,88:252-9
[19] Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.Liver Int,2020,40:1578-1589.
[20] Yim HJ, Kim IH, Suh SJ,et al. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial. J Viral Hepat,2018,25:1321-1330.
[21] Lu L, Yip B, Trinh H,et al. Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir.J Viral Hepat,2015,22:675-81.
[22] Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).J Hepatol,2014,61:777-84.
[23] 金怡,黄春洋 ,魏飞力,等,联合治疗策略在应答不佳/耐药HBeAg阳性慢性乙型肝炎患者中的临床研究,传染病信息,2015,28:273-278. |
